Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Camidanlumab Tesirine
Synonyms
Therapy Description

Camidanlumab Tesirine is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Camidanlumab Tesirine ADCT-301 Camidanlumab Tesirine (ADCT-301) is a human nomoclonal antibody against CD25 in conjugation with pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Hodgkin's lymphoma not applicable Camidanlumab Tesirine Phase I Actionable In a Phase I trial, Camidanlumab Tesirine treatment resulted in an objective response rate of 63.6% (14/22) and a complete response rate of 27.3% (6/22) in Hodgkin's lymphoma patients (Blood 2017 130(Suppl 1):1510; NCT02432235). detail...
Unknown unknown non-Hodgkin lymphoma not applicable Camidanlumab Tesirine Phase I Actionable In a Phase I trial, Camidanlumab Tesirine treatment resulted in partial response in 15.8% (3/19) in non-Hodgkin lymphoma patients (Blood 2017 130(Suppl 1):1510; NCT02432235). detail...

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT02432235 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Completed
NCT04052997 Phase II Camidanlumab Tesirine Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting


Additional content available in CKB BOOST